ALFA Finder| Management target | Revenue 15.0% FY27 |
|---|
| Revenue growth | 28% YoY growth in Q1 FY27. |
|---|---|
| Margins | Targeting 15%+ EBITDA margins as capacity utilization improves. |
| Demand visibility | Positive momentum in domestic and international specialty chemicals. |
| Management confidence | Bullish on prospects, especially international markets and new product ramps. |
Growth
Consolidated revenue grew 28% YoY; HPPC, TSC, and AHN segments each grew approximately 28% YoY; Exports up 21%.
Outlook
Management targets 15% top-line growth for FY27 and aims for 15%+ steady-state EBITDA margins through B2C rationalization.
Risks
EBITDA margins compressed to 11.6% from 12.5% due to raw material volatility, freight costs, and B2C segment losses.
Last quarter's promises, checked
Delivered
- Guided 15% revenue growth → delivered 28% (= BEAT)
- Guided 12-13% EBITDA margin → delivered 11.6% (= PARTIAL)
- Guided Thailand plant operational Q2 → delivered operational (= BEAT)
Partly delivered
- Guided debt reduction/debt-free 18mo → delivered net debt Rs. 248 Cr (= PARTIAL)
Missed
- Guided B2C/Institutional breakeven FY27 → delivered losses (= MISS)
Investor Presentation filed with NSE, NSE: ROSSARI. Summary written with AI assistance from the document.
Rossari Biotech Ltd: key numbers
- Share price
- ₹432.80
- Market cap
- ₹2,397 Cr
- Revenue (annual)
- ₹2,396 Cr
- Net profit (annual)
- ₹149.2 Cr
- P/E (TTM)
- 15.7×Sector 35.5×
- Promoter holding
- 68.14%+0.00% QoQ
- FII holding
- 1.84%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Rossari Biotech Ltd
All →Rossari Biotech Earnings Call Transcript: Key Takeaways
Rossari Biotech achieved record quarterly revenue and EBITDA despite volatile raw material costs and logistical headwinds.
- Call
- Guides 15% growth
Rossari Biotech Results Update
Rossari Biotech reported Q2 FY27 revenue of Rs. 697.6 crore, up 19% YoY. The company also announced plans for a new manufacturing facility in Saudi Arabia.
Rossari Biotech Investor Presentation: Key Takeaways
Rossari Biotech reported record quarterly revenue of Rs. 697.6 Cr (up 19% YoY) and EBITDA of Rs. 87 Cr (up 21% YoY). Performance driven by volume and product mix.
Rossari Biotech Q2 FY27 Results: Net Profit ₹38.9 Cr, Up 5.4% YoY
Rossari Biotech Ltd reported revenue from operations of ₹697.6 Cr (+19.0% YoY) and net profit of ₹38.9 Cr (+5.4% YoY) for Q2 FY27.
- Key figure
- Net profit ₹38.9 Cr · +5.4% YoY
Rossari Biotech Other Announcement
Rossari Biotech submitted its quarterly shareholding pattern for the period ended September 30, 2026. The filing includes minor reporting adjustments for two promoter group members.
Rossari Biotech Board Meeting Date
Rossari Biotech will hold a board meeting on October 17, 2026, to consider and approve its unaudited financial results for the quarter ending September 30, 2026.